353
Participants
Start Date
March 29, 2017
Primary Completion Date
March 1, 2032
Study Completion Date
March 1, 2032
Nivolumab
Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
Ipilimumab
Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
Celecoxib 200mg
celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
BMS-986253
BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
BMS-986016
Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29, in cohort 7 160mg on day 1, day 29 and day 57
RECRUITING
Marieke van de Belt, Amsterdam
RECRUITING
OLVG, Amsterdam
RECRUITING
Catharina Ziekenhuis, Eindhoven
RECRUITING
Spaarne Ziekenhuis, Haarlem
NOT_YET_RECRUITING
Tergooi, Hilversum
NOT_YET_RECRUITING
Haga ziekenhuis, The Hague
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
The Netherlands Cancer Institute
OTHER